Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12275-021-0617-7 http://scihub22266oqcxt.onion/10.1007/s12275-021-0617-7 33527314!7849956!33527314     free     free     free       J+Microbiol 2021 ; 59 (2): 124-131 Nephropedia Template TP {{tp|p=33527314|t=2021. Raloxifene as a treatment option for viral infections |pdf=|usr=}}{{33527314}} gab.com Text Raloxifene as a treatment option for viral infections JO: J Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33527314 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene's mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections. Twit Text FOAVip Raloxifene as a treatment option for viral infections ????J Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33527314 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33527314 #FOAvip English Wikipedia <ref>{{Cite pmid|33527314}}</ref> Raloxifene as a treatment option for viral infections #MMPMID33527314 Hong S; Chang J; Jeong K; Lee W J Microbiol 2021[Feb]; 59 (2): 124-131 PMID33527314show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene's mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Antiviral Agents/*therapeutic use[MESH] |Estrogen Antagonists/therapeutic use[MESH] |Estrogens/agonists[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Osteoporosis, Postmenopausal/drug therapy[MESH] |Raloxifene Hydrochloride/*therapeutic use[MESH] |SARS-CoV-2/*drug effects[MESH]Raloxifene as a treatment option for viral infections (epmc).pdf DeepDyve Pubget Overpricing